RCAG
AMRX icon

Rehmann Capital Advisory Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Rehmann Capital Advisory Group’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-56
Closed -$793 – 2070
2019
Q1 		$793 Hold
56
– – ﹤0.01% 1966
2018
Q4 		$757 Hold
56
– – ﹤0.01% 1704
2018
Q3 		$1.24K Hold
56
– – ﹤0.01% 1937
2018
Q2 		$919 Buy
+56
New +$983 ﹤0.01% 1990

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Rehmann Capital Advisory Group's AMRX Position: Q2 2019 in Review

Rehmann Capital Advisory Group sold out of Amneal Pharmaceuticals (AMRX) in Q2 2019, closing a stake of 56 shares — an estimated $793 sold.

Rehmann Capital Advisory Group first reported a position in AMRX in Q2 2018 and held it in 4 quarters. The position peaked at $1.24K in Q3 2018. 129 funds tracked by Wall St. Rank hold AMRX as of Q2 2019.

  • Rehmann Capital Advisory Group reported no remaining Amneal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 56 Amneal Pharmaceuticals shares in Q2 2019, an estimated $793.
  • Rehmann Capital Advisory Group first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Rehmann Capital Advisory Group's Amneal Pharmaceuticals position peaked at $1.24K in Q3 2018.
  • 129 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q2 2019, filed 27 Aug 2019.